News

Partners of STD Patients Targeted For Treatment


 

NEW YORK. — Asking patients to deliver therapy for sexually transmitted diseases to their sexual partners is paying off, with increases in the proportion of partners who are being treated, according to data from researchers in Washington state.

The Centers for Disease Control and Prevention advises that expedited partner therapy (EPT), or treating sexual partners without requiring that they first seek a medical evaluation, is an option when other strategies are impractical or unsuccessful.

In Washington state, public health officials advise that EPT should be given when treatment cannot otherwise be enssured, according to Dr. Matthew Golden, director of the STD Control Program for Public Health in Seattle/King County.

But EPT isn't a cure-all, Dr. Golden said at a joint conference of the American Sexually Transmitted Diseases Association and the British Association for Sexual Health and HIV. Some people will not get their partners treated, such as those with more than one sex partner or a partner they are unikely to have sex with again, men who have sex with men, and those who say outright they won't notify their partners.

So King County health officials developed a case report form that allows the diagnosing physician to check a box indicating that the health department should assume responsibility for partner notification, such as drawing on the services of a disease intervention specialist. Through the program, patients and their partners have free access to medications through large clinics and commercial pharmacies.

Use of the form has yielded encouraging results. A random sample of patients diagnosed with gonorrhea or chlamydia shows about 39% were classified as having all partners treated before the intervention, compared with 65% in the postintervention period (Sex. Transm. Dis. 2007;34:598-603).

If the results continue, the researchers estimate there would be about a 25% reduction in chlamydial prevalence in about 2 years' time and a 50% reduction in chlamydial prevalence in 4 years' time. A community-level, randomized controlled trial is being conducted throughout the state to establish whether EPT reduces the prevalence of chlamydial infection and the incidence of gonorrhea at a population level.

Recommended Reading

DTaP Vaccine Now Cleared for All Five Doses
MDedge Family Medicine
Face the Facts When Dealing With Genital Herpes : Patient education is critical, especially since many who test positive are asymptomatic.
MDedge Family Medicine
Gonorrhea Often Goes Undetected in Gay Men
MDedge Family Medicine
Self-Collected Swabs Okay for STDs in Men
MDedge Family Medicine
Antibiotics for Otitis Media Tied to Resistance Rates
MDedge Family Medicine
Travel, Vaccine Exemptors Are Cited in Rise in Measles Cases
MDedge Family Medicine
Necrotizing Pneumonia on the Rise in Pediatric Populations
MDedge Family Medicine
Zoster Vaccine Advised for Adults 60 and Older
MDedge Family Medicine
Fluoroquinolone Resistance Rises In Older Patients
MDedge Family Medicine
Dengue Edges In to U.S., Especially Texas, Florida
MDedge Family Medicine